SAN DIEGO--(BUSINESS WIRE)--Sequenom, Inc. (NASDAQ:SQNM) today announced that it has entered into agreements to issue and sell an aggregate of 3,383,335 shares of its common stock at $9.00 per share to certain investors. The aggregate net proceeds of the private placement, after deducting the placement agents’ fees and estimated offering expenses payable by Sequenom, are expected to be approximately $28 million. Sequenom intends to use the net proceeds from the financing to advance its research, development and commercialization of various diagnostic tests, as well as for general corporate purposes. Lehman Brothers Inc. and UBS Investment Bank served as joint-lead placement agents for Sequenom in the private placement and Oppenheimer & Co. Inc., Leerink Swann LLC and Rodman & Renshaw, LLC, a wholly owned subsidiary of Rodman & Renshaw Capital Group, Inc. (NASDAQ:RODM), served as co-placement agents for Sequenom in the private placement.
